The earnings call highlighted the successful launch and positive early performance of GRAFAPEX, along with strategic achievements such as NTAP reimbursement approval and improved gross margins. However, these were balanced by challenges including declining revenues and adjusted EBITDA, increased expenses, and concerns about tariffs affecting costs. The overall sentiment is cautious optimism, with focus on future growth driven by GRAFAPEX.

Company Guidance

During the Medexus Pharmaceuticals First Quarter 2026 conference call, the company provided detailed guidance on the financial metrics and strategic progress achieved. GRAFAPEX's commercial launch was highlighted, contributing $3 million to product-level net revenue in fiscal Q1 '26, with expectations to reach $3 million to $3.5 million in fiscal Q2 '26. GRAFAPEX has already been adopted by 36 transplant centers, representing 24% of allo-HSCT procedures in the U.S., and received Medicare's NTAP reimbursement approval, allowing eligible patients up to $21,411 in additional reimbursement starting October 1, 2025. Overall, the company reported fiscal Q1 '26 revenue of $24.6 million, down from $27.3 million the previous year, with adjusted EBITDA at $3.4 million, compared to $6.1 million last year. Despite a decrease in net income to $0.5 million from $2 million, Medexus remains optimistic, with GRAFAPEX expected to positively impact cash flows by fiscal Q3 '26. Meanwhile, the Canadian portfolio experienced changes due to the loss of Rupall's exclusivity, with revenues decreasing as expected. The company maintained a strong focus on strategic opportunities, including potential new products and debt refinancing, while navigating a 15% tariff on branded pharmaceuticals imported from the EU, impacting GRAFAPEX and Rasuvo.

Successful Launch of GRAFAPEX

GRAFAPEX generated $3 million in product-level net revenue in fiscal Q1 '26, with early adoption by major commercial payers and healthcare institutions. 36 of 180 transplant centers, representing 24% of total allo-HSCT procedures in the U.S., have ordered GRAFAPEX.

Positive NTAP Reimbursement for GRAFAPEX

Secured approval for NTAP reimbursement for GRAFAPEX from Medicare, providing up to $21,411 of additional reimbursement per eligible patient starting October 1, 2025.

Trecondyv Growth in Canada

Unit demand for Trecondyv grew 38% over the trailing 12-month period, with BC, Manitoba, Ontario, and Quebec executing listing agreements for reimbursement.

Gross Margin Improvement

Gross margin improved to 56.0% in fiscal Q1 '26 from 54.4% in the same period last year.

Debt Reduction

Net debt decreased to $12.6 million as of June 30, 2025, compared to $13.2 million as of March 31, 2025.

Medexus Pharmaceuticals Inc (TSE:MDP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:MDP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2026 (Q2)	-0.02 / -	0	―	―	―
Aug 12, 2025	2026 (Q1)	-0.04 / 0.03	0.11	-75.00% (-0.08)	―	―
Jun 25, 2025	2025 (Q4)	-0.09 / -0.03	0.043	-164.52% (-0.07)	―	―
Feb 05, 2025	2025 (Q3)	0.05 / 0.04	-0.028	250.00% (+0.07)	―	―
Nov 07, 2024	2025 (Q2)	0.03 / 0.00	-0.069	―	―	―
Aug 07, 2024	2025 (Q1)	0.07 / 0.11	0.041	166.67% (+0.07)	―	―
Jun 25, 2024	2024 (Q4)	-0.02 / 0.04	0.469	-90.88% (-0.43)	―	―
Feb 07, 2024	2024 (Q3)	0.08 / -0.03	-0.097	71.43% (+0.07)	―	―
Nov 08, 2023	2024 (Q2)	0.00 / -0.07	-0.193	64.29% (+0.12)	―	―
Aug 09, 2023	2024 (Q1)	0.01 / 0.04	-0.097	142.86% (+0.14)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:MDP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	C$2.75	C$2.67	-2.91%
Jun 25, 2025	C$3.35	C$3.15	-5.97%
Feb 05, 2025	C$3.79	C$3.05	-19.53%
Nov 07, 2024	C$2.20	C$2.17	-1.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Medexus Pharmaceuticals Inc (TSE:MDP) report earnings?

Medexus Pharmaceuticals Inc (TSE:MDP) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Medexus Pharmaceuticals Inc (TSE:MDP) earnings time?

Medexus Pharmaceuticals Inc (TSE:MDP) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:MDP EPS forecast?

TSE:MDP EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing